spinofflive
Unsorted electric batteries at the Megapolisresurs recycling plant for household batteries, automotive batteries, and other disposed electronic products (Photo: Nail FattakhovTASS via Getty Images)
Unsorted electric batteries at the Megapolisresurs recycling plant for household batteries, automotive batteries, and other disposed electronic products (Photo: Nail FattakhovTASS via Getty Images)

ScienceOctober 23, 2020

How high-tech recycling could stop waste batteries becoming the next plastic crisis

Unsorted electric batteries at the Megapolisresurs recycling plant for household batteries, automotive batteries, and other disposed electronic products (Photo: Nail FattakhovTASS via Getty Images)
Unsorted electric batteries at the Megapolisresurs recycling plant for household batteries, automotive batteries, and other disposed electronic products (Photo: Nail FattakhovTASS via Getty Images)

To celebrate Recycling Week, Vanessa Young explains the essential role of nano-recycling in making the most of the tiny-scale but potentially harmful waste from batteries, circuit boards and more

For most of us recycling means jars, bottles, tins (and the sprint to get the bin out as the truck comes up the street). If we get fancy, we might think about the different types of plastic and what can and cannot be recycled. Beyond that we don’t generally give it much thought. 

But there’s a whole world of recycling that we literally can’t see: nano-recycling. Although not yet in the Oxford Dictionary, nano-recycling is happening in labs all around this country. And no, it isn’t when your neighbour only recycles a small amount of their waste. We’re talking about upcycling the lithium from battery cathodes, pulling the gold out of e-waste, recycling proteins from hoki fish eyes into corneal tissue, and recycling acid waste from the galvanised steel industry. 

What these all have in common is that they involve materials science and the nanoscale. 

Working with hoki fish eyes, a waste by-product from the fishing industry, Dr Laura Domigan extracts sufficient quantities of nanoscale crystallin proteins to look at using these to repair or replace corneal tissue in human eyes, and to make transparent biomaterials – namely thin films, gels and adhesives.

Dr Laura Domigan (Photo: supplied)

The cornea is the exquisitely composed tissue that covers the eye. It can tear and malfunction for a variety of reasons, and need replacing or repairing. “Over 250 corneal transplants are performed in New Zealand every year, but as with all organ transplants, the number is limited by donors. There simply aren’t enough of them,” says Domigan

Domigan, a MacDiarmid Institute and University of Auckland researcher, says her dream is to be able to construct or repair a structure that nature has taken billions of years to design: the eye.

She is collaborating with her colleagues in the department of ophthalmology at the Faculty of Medical and Health Sciences to make synthetic or naturally derived surgical products and implants.  “It’s like any materials science problem – we need to look for the properties we need, and then search and experiment with materials till we find the right one,” she says.

It’s not the only nanoscale work going on in her lab. Each month a couple of her students head to a slaughterhouse in Auckland’s Great South Road to collect blood in 2L bottles. Back at the university, they extract haemoglobin from the waste and nano-recycle it, electrospinning it into nanofibres for fibrous scaffolds to mimic natural tissue, with potential applications in medicine.

“These biomaterials, like the hoki fish eye proteins, may be good for tissue engineering, or could be turned into bio-based inks for 3D printing,” she says. 

The eyes have it (Photo: supplied)

Currently most electronic waste (e-waste) heads into landfills, where it becomes a modern-day buried treasure. The gold discarded as e-waste worldwide is estimated to be worth an estimated NZ$37 billion per year alone. 

Mint Innovation is reclaiming high value elements from e-waste, using chemistry and microbes to pull out gold, copper and palladium from the green printed circuit boards in old computers, and recycling the other components including plastic, ceramics and glass fibres into building materials

The concentration of gold in printed circuit boards is 50-100 times higher than in gold ore, says R&D lead Dr Rob Staniland. As he explains it, Mint Innovation’s process dissolves the elemental gold, after which the bacteria then act like molecular sponges, sucking up the gold ions selectively.

The startup won Most Innovative Deep Tech Solution at the Hi-Tech Awards this year, and is looking to expand its “urban mining” operations, building plants next year in Australia and the UK. There are well-paved roads to the company itself from university labs, with five MacDiarmid Institute alumni (including Staniland himself) now working for the company.

The growth in EVs presents a need to find better ways of recycling their batteries (Photo: The Warehouse Group)

A significant amount of research is being done to prevent batteries becoming the next plastic waste crisis. A battery dies because the electrode loses functionality. Batteries can be smelted down – but this leaves a huge carbon footprint.

The Ministry of Transport predicts New Zealand will have 1.9 million EVs by 2039/40 and this presents a huge need to find better ways of recycling batteries. Peng Cao, a MacDiarmid Institute researcher and associate professor in chemical and materials engineering at the University of Auckland. says smelting and extracting valuable metals is viable only for the first generation of batteries, as the second generation have much less or even no cobalt and are therefore less valuable.

“Considering that car batteries have an 8-10 year lifespan, with EVs increasing in number so much, in ten years’ time this will be a problem,” says Cao. “Car batteries will become another plastics disaster if we don’t start working right now.”

Cao is part of a Vector Energy-led battery innovation working group of New Zealand companies and researchers. Based at the University of Auckland, he is working at the nanoscale to upcycle lithium from cathodes, and refurbishing the electrode with lithium, nickel, cobalt and manganese. 

Zincovery’s Thomas Hughes melting and molding some recovered zinc (image: supplied).

New Zealand companies are leading the way in ensuring industries are making better use of their waste. Zincovery is a new startup that recycles the galvanising industry’s spent acid and zinc for reuse as valuable raw materials. Aaron Marshall, lead researcher and associate professor at the University of Canterbury‘s Biomolecular Interaction Centre, has developed a process which recovers high purity zinc, iron and acid from material that would otherwise become expensive landfill waste. The University of Canterbury and MacDiarmid Institute-affiliated company joins other New Zealand startups like Mint and Avertana that mine industrial wastes into valuable commodities.

Jonathan Ring co-founded Zincovery – winner of this year’s C-Prize for environmental tech innovation based on research for his 2018 Masters degree in chemical and process engineering. By  recycling zinc, the Zincovery technology reduces and cleans up pollution, while also producing other commercial benefits

“I want to drive change in the way industries think about waste,” he says.

So as we make our weekly dash for the recycling truck, we know we’re all small parts of a big puzzle when it comes to recycling. As nano-recycling shows, even the very tiny can make a big impact. 

This content was created in paid partnership with The MacDiarmid Institute. Learn more about our partnerships here.

Keep going!
Recruitment for the study began in March. Photograph: Richard Adams
Recruitment for the study began in March. Photograph: Richard Adams

ScienceOctober 23, 2020

My life as a human guinea pig on the Oxford Covid vaccine trial

Recruitment for the study began in March. Photograph: Richard Adams
Recruitment for the study began in March. Photograph: Richard Adams

At the forefront of the race for a coronavirus vaccine are researchers at Oxford University, who are working ‘with great care and due haste’. Six months ago, several hundred volunteers began participation in a clinical trial of the vaccine. Among them was UK-based NZ journalist Richard Adams.

I can’t talk now, I told the caller, because I’m about to go into a hospital. Since it was April 2020, telling anyone that you were at a hospital required more explanation than usual, so I told him: I was about to be injected with the new Covid-19 vaccine being developed by Oxford University.

Oxford’s vaccine trial had started four days earlier, when the first two human subjects were injected and filmed and broadcast across the world. Two days later, two more were injected. And two days after that, there was me, lost in the carpark of the Churchill hospital.

“You’re very brave,” my caller said. But up until then, bravery had nothing to do with it. To be honest, I signed up more in fear of boredom than anything else.

The Oxford vaccine trial launched with little publicity, because it began so early, at the height of international panic but before the reality of the long and debilitating nature of the Sars-CoV-2 virus had emerged. I only heard about the vaccine trial through my colleague, Hannah Devlin, the Guardian’s science correspondent.

For anyone who lives in Oxford and is feeling brave: the first UK vaccine trial is now recruiting,” she tweeted on March 27. Lockdown in the UK had begun the week before. All but essential staff were working from home. Schools and universities had emptied, conferences and exams were cancelled, meaning that, as the Guardian’s education editor, I (temporarily) had not much to do.

So I followed the link on Hannah’s tweet, expecting a grand scheme. But this was very local: volunteers had to live near Oxford, be aged between 18 and 55, and healthy. And not have had Covid-19. So I filled in an online form with the usual stuff. Medical history. Allergies. Contact details. No, I’d never taken part in a paid medical trial before – wait, we get paid?

“Volunteers will be required to make multiple visits over several months and must commit to remaining in Oxford for that time …” Well, I wasn’t going anywhere, and neither was anyone else. The railway line to London runs close to my house, and entire inter-city trains – normally carrying hundreds of commuters at rush hour – were going by with hardly a soul on board.

But then things moved quickly: the next day an email invited me to a screening. When was I available? I looked at an empty calendar and replied: anytime. An hour later another email arrived telling me to come the next day, for two and a half hours. And in another sign of seriousness, there would be free carparking, an unheard of event in Oxford.

Help protect the world from a health crisis, and get free parking, too. Photo: Richard Adams.

By this point in April, the centre of Oxford was deserted. The students and tourists had gone, the hotels, museums, colleges and restaurants all closed. Without any traffic the drive across the city took just minutes, meaning I arrived very early. The carparks were all but empty anyway, Oxford’s hospitals having cancelled appointments and barred visitors. Ambulances were the only things on the road, and the few people around were fully gowned and visored.

But not at the the Centre for Clinical Vaccinology and Tropical Medicine, where screening was to take place. Outside were some nervous young interns with lists of names. No masks or gowns for them, or us, or even hand sanitiser, unsurprising given the severe national shortage in England at the time.

I was given a sticker with the number 5 on it and taken to see a socially distanced video of Adrian Hill, the director of Oxford’s Jenner Institute, explaining what was happening. There were then legal documents to be signed disclaiming any liability on the part of the University of Oxford for eternity, and a form for bank details. So we did get paid.

Oxford, emptied by coronavirus. Photo: Richard Adams

Then there were interviews, physical examinations, tests and more tests, including blood tests, the first of many, increasingly painfully. But I didn’t know that then, thankfully. That day around 700 people in the UK died from Covid-related causes.

Some phone calls followed with questions – I’d been to Italy in February, where had I gone exactly? – and finally another email inviting me to be vaccinated, on Day 0 in group one of phase one of the trial.

Perhaps because things had moved so quickly I hadn’t really thought about the dangers until that carpark phone call on Day 0. It was a university vice-chancellor. “You’re very brave,” he said, “I couldn’t do it.” I laughed it off, saying that after all the things I’d written about the University of Oxford it only seemed fair they should have a shot at killing me. But for the first time I felt properly nervous.

Adrian Hill had explained that because this was the first human trial, and the usual testing had been sped-up, there could be unexpected side-effects. And in some earlier cases, animals injected with experimental Sars vaccines had more severe symptoms when they were later infected than those that hadn’t been vaccinated.

I remembered that I’d posted a link to the trial sign-up on the local parents WhatsApp group, which was full of eager messages from parents wanting to support the NHS. No one replied.

But this was a randomised controlled trail – meaning that 50% of the volunteers would receive the officially titled ChAdOx1 nCoV-19 vaccine, the other half would get an unrelated meningitis vaccine, and no one would know who got which until the trial ends in six months. And Sarah Gilbert, Oxford’s professor of vaccinology, had told journalists she was 80% confident of success. So I figured that a 50% chance of an 80% chance was pretty good odds. 

Now the interns were gone, replaced by security guards outside the clinic. Inside I glimpsed Professor Gilbert, who’d been in the media since the first injections four days earlier. A doctor took me off for more tests. “Your blood pressure is very high,” she said. I admitted being nervous. Don’t worry, she said, they’ve injected five chimpanzees with the vaccine and four of them are fine.

Despite the high blood pressure, finding my veins proved difficult until a passing paediatrician helped me fill up the six vials of blood required. Meanwhile nurses cursed the flimsy aprons they had to wear, which ripped too easily. “There are meant for hairdressers,” one said in disgust.

Then after more blood came the vaccine itself, which looked and felt like a flu jab. I was ushered off to an observation room for an hour, “just in case”. Then more tests, and another zip home through the empty streets. I felt fine but tired, I told the follow-up phone call that evening, and started filling in a web diary every day for a month to come.

The next day I felt very tired indeed but there was none of the swelling or redness at the injection site that we had been warned to watch for, and by day three when I returned for more tests, everything seemed back to normal.

Except for my veins, which refused to give up their blood without a struggle. The same happened again on day seven and day 14, by which point my arms had seen more needles in three weeks than the rest of my life put together. One nurse said my vein went flat as soon as the needle went in, so nothing came out. Another doctor said my vein jumped about, causing some very painful attempts to pin it down.

So I learned that some people are much better at taking blood than others. And I learned that before a blood test it helps to eat lots of food and drink lots of fluids – coffee is not so good but tea is fine. Also, I’d be a rubbish heroin addict.

Then things slowed down, the diary became a depressing weekly record of lockdown life. “How many times did you go to the pub/club/theatre this week?” – zero didn’t even come close to the truth. Every sore throat or runny nose in my household had to be recorded, followed by “outcome of illness”: recovered or died.

Each visit to the CCTVM saw it grow and become more professional. The flapping paper signs with directions were replaced with laminated logos. A vast mobile building was unfolded on one edge of the car park, and became the new centre for testing. The building was normally trucked around to music festivals like Glastonbury, a nurse told me, but they had all been cancelled.

A mobile building trucked in to house researchers. Photo: Richard Adams

As summer passed, the trial expanded from Oxford to other cities and countries. People like Boris Johnson have buoyantly talked up its chances. The US government bought hundreds of millions of doses in advance. Newspapers wrote articles about “the race for the vaccine” as if it was an inevitable success.

Those articles were usually illustrated by scientists in gleaming labs, and maybe there were some, but from outside it wasn’t obvious. The Jenner Institute building itself is modern. But around it on the sprawling hospital campus are derelict buildings, smashed glass, collapsing roofs, broken furniture. The staff carpark is dirt and gravel, dusty in summer and muddy the other three seasons. The hopes of the world and billions of dollars might be resting on it, but within sight of the centre are abandoned offices with blinds poking out of broken windows – another side of the UK’s  health system exposed by this pandemic.

Soon I’ll be making a final visit for the Day 182 tests, when the trial ends. It doesn’t seem like six months have passed since Day 0. Maybe that’s because as I write this, Oxfordshire has recorded 100 new infections in a day, Oxford’s hospitals seen their first Covid-related death since mid-summer, and most of the UK and Europe are being locked down again. I still don’t feel brave.